Tolmar's Fensolvi Received the US FDA's Approval to Treat Pediatric Patients Two Years of Age and Older withntral Prec Ceocious Puberty (CPP)
Shots:
- The approval is based on P-III study which involves assessing of leuprolide acetate (LA-45 mg) in 64 children with central (gonadotropin-dependent) precocious puberty evaluating its safety and pharmacokinetics
- The study achieved its 1E i.e. 87% of children achieved a serum luteinizing hormone concentration of <4 IU/L at six months post injection with most common TEAEs were injection site pain (31%)- nasopharyngitis (22%)- and fever (17%)
- Fensolvi (leuprolide acetate) is a novel six-month- subcutaneous leuprolide acetate an gonadotropin releasing hormone (GnRH) agonist with small injectable suspension pproved for the treatment of pediatric patients two years of age and older with Central Precocious Puberty
Click here to read full press release/ article | Ref: Tolmar | Image: Tolmar
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com